Cargando…

A Novel CXCR4 antagonist enhances angiogenesis via modifying the ischaemic tissue environment

Endothelial progenitor cells (EPCs) play a capital role in angiogenesis via directly participating in neo‐vessel formation and secreting pro‐angiogenic factors. Stromal cell‐derived factor 1 (SDF‐1) and its receptor CXCR4 play a critical role in the retention and quiescence of EPCs within its niche...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Xiaoqing, Dai, Xiaozhen, He, Luqing, Ling, Xiao, Shao, Minglong, Zhang, Chi, Wang, Yuehui, Xiao, Jian, Cai, Lu, Li, Xiaokun, Tan, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618675/ https://www.ncbi.nlm.nih.gov/pubmed/28374486 http://dx.doi.org/10.1111/jcmm.13150

Ejemplares similares

The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells
por: Dai, Xiaozhen, et al.
Publicado: (2011)

Sitagliptin‐mediated preservation of endothelial progenitor cell function via augmenting autophagy enhances ischaemic angiogenesis in diabetes
por: Dai, Xiaozhen, et al.
Publicado: (2017)

Interleukin‐1β augments the angiogenesis of endothelial progenitor cells in an NF‐κB/CXCR7‐dependent manner
por: Fan, Xia, et al.
Publicado: (2020)

FGF21 promotes ischaemic angiogenesis and endothelial progenitor cells function under diabetic conditions in an AMPK/NAD+‐dependent manner
por: Dai, Qiaoxia, et al.
Publicado: (2021)

An Enriched Environment Enhances Angiogenesis Surrounding the Cingulum in Ischaemic Stroke Rats
por: Shen, Xueyan, et al.
Publicado: (2020)

CXCR4 antagonists for treatment of breast cancer
por: Cortés, Javier, et al.
Publicado: (2018)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers
por: Katkoori, Venkat R., et al.
Publicado: (2015)

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

Endothelial FAM3A positively regulates post-ischaemic angiogenesis
por: Xu, Wenjing, et al.
Publicado: (2019)

Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability
por: Harms, Mirja, et al.
Publicado: (2023)

Erratum. Metallothionein Preserves Akt2 Activity and Cardiac Function via Inhibiting TRB3 in Diabetic Hearts. Diabetes 2018;67:507–517
por: Gu, Junlian, et al.
Publicado: (2020)

TMAO-Activated Hepatocyte-Derived Exosomes Impair Angiogenesis via Repressing CXCR4
por: Liu, Xiang, et al.
Publicado: (2022)

Serum tissue inhibitor of metalloproteinase‐1 and risk of cognitive impairment after acute ischaemic stroke
por: Ge, Jinzhuo, et al.
Publicado: (2020)

Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases
por: Cheng, Peng, et al.
Publicado: (2016)

Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
por: Khan, Abid, et al.
Publicado: (2007)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

EPI-X4, a novel endogenous antagonist of CXCR4
por: Buske, Christian, et al.
Publicado: (2015)

CXCR4 antagonists suppress small cell lung cancer progression
por: Taromi, Sanaz, et al.
Publicado: (2016)

Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer
por: Gong, Zhenqiang, et al.
Publicado: (2018)

CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro
por: Qian, Tingting, et al.
Publicado: (2018)

Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells
por: Zheng, Ke, et al.
Publicado: (2010)

A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys
por: Fang, Xiao, et al.
Publicado: (2021)

Multiple Low-Dose Radiation Prevents Type 2 Diabetes-Induced Renal Damage through Attenuation of Dyslipidemia and Insulin Resistance and Subsequent Renal Inflammation and Oxidative Stress
por: Shao, Minglong, et al.
Publicado: (2014)

Low-Dose Radiation Activates Akt and Nrf2 in the Kidney of Diabetic Mice: A Potential Mechanism to Prevent Diabetic Nephropathy
por: Xing, Xiao, et al.
Publicado: (2012)

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
por: Morimoto, Mamoru, et al.
Publicado: (2016)

Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging
por: Peng, Yanli, et al.
Publicado: (2019)

Plumbagin Restrains Hepatocellular Carcinoma Angiogenesis by Stromal Cell-Derived Factor (SDF-1)/CXCR4-CXCR7 Axis
por: Zhong, Jing, et al.
Publicado: (2019)

Inhibition of Angiogenesis, Fibrosis and Thrombosis by Tetramethylpyrazine: Mechanisms Contributing to the SDF-1/CXCR4 Axis
por: Cai, Xiaoxiao, et al.
Publicado: (2014)

Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4
por: Chi, Jhih-Ying, et al.
Publicado: (2021)

A Novel Mechanism by Which SDF-1β Protects Cardiac Cells From Palmitate-Induced Endoplasmic Reticulum Stress and Apoptosis via CXCR7 and AMPK/p38 MAPK-Mediated Interleukin-6 Generation
por: Zhao, Yuguang, et al.
Publicado: (2013)

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
por: Parameswaran, Reshmi, et al.
Publicado: (2011)

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
por: Tamamura, Hirokazu, et al.
Publicado: (2008)

PET imaging of CXCR4 using copper-64 labeled peptide antagonist
por: Jacobson, Orit, et al.
Publicado: (2011)

Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
por: Mishra, Rama K., et al.
Publicado: (2016)

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
por: Koenig, Lars M., et al.
Publicado: (2020)

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
por: Song, Jen-Shin, et al.
Publicado: (2021)

Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t
por: Ward, Richard J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vca4nji30hcc2iuklejtjgmhfu